Drugs / KP-1199
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03880487 | Mar 2019 → Apr 2020 | pain agnosia | Kalyra Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KP-1199 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03880487 ↗ |
| Route | Oral | “KP-1199 oral capsules” NCT03880487 ↗ |